Newswise — Researchers have developed genetically modified pigs that are protected from classical swine fever virus (CSFV), according to a study published December 13 in the open-access journal PLOS Pathogens by Hongsheng Ouyang of Jilin University, and colleagues. As noted by the authors, these pigs offer potential benefits over commercial vaccination and could reduce economic losses related to classical swine fever.
CSFV is responsible for a highly contagious, often fatal disease that causes significant economic losses. Due to the economic importance of this virus to the pig industry, the biology of CSFV has been investigated extensively. Despite efforts by many government authorities to stamp out the disease from pig populations, it remains widespread, and it is only a matter of time before the virus is reintroduced and the next round of disease outbreaks occurs. There is an urgent need to develop effective approaches to eradicate CSFV. To address this challenge, Ouyang and colleagues generated CSFV-resistant pigs by combining a gene-editing tool called CRISPR/Cas9 with RNA interference (RNAi), a technique that silences gene expression.
The researchers demonstrated that these pigs could effectively limit the replication of CSFV and reduce CSFV-associated clinical signs and mortality. Moreover, disease resistance could be stably transmitted to first-generation offspring. Currently, the researchers are conducting long-term studies to monitor the safety and effectiveness of this approach as these animals age. According to the authors, generating anti-CSFV pigs using a genome editing-based strategy could be a direct and effective approach to facilitate the permanent introduction of novel disease resistance traits into the mass population of production pigs via conventional breeding techniques. In addition, this antiviral strategy can be applied to other domestic species and could provide insights for future antiviral research.
Ouyang adds, “These tansgenic pigs could effectively limit the replication of CSFV and reduce CSFV-associated clinical signs and mortality.”
Funding: This work was financially supported through a grant from the Special Funds for Cultivation and Breeding of New Transgenic Organisms (No. 2016ZX08006003), the Program for JLU Science and Technology Innovative Research Team (2017TD-28), the Program for Changjiang Scholars and Innovative Research Team in University in China (No. IRT16R32) and the Fundamental Research Funds for the central Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Jilin Provincial Key Laboratory of Animal Embryo Engineering, Institute of Zoonosis, College of Animal Sciences, Jilin University, 130062, Changchun, Jilin Province, People’s Republic of China
Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, Jilin Province, People’s Republic of China
In your coverage please use this URL to provide access to the freely available paper:http://journals.plos.org/
Press-Only Preview of the Article: https://sforce.co/2SK7Z49
Telephone: (86) 431-87836175
Email: [email protected]
About PLOS Pathogens
PLOS Pathogens is the first Open Access journal for breakthroughs in understanding pathogens and their interactions with host organisms. The journal publishes original research and commentary that yield novel insights into pathogenesis that are of broad interest and importance to researchers studying pathogens and pathogen-host interactions. For more information, visit http://journals.plos.
Media and Copyright Information
For information about PLOS Pathogens relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit http://journals.plos.
PLOS journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited.
About the Public Library of Science
Public Library of Science (PLOS) is a nonprofit Open Access (OA) publisher, innovator and advocacy organization dedicated to accelerating progress in science and medicine by leading a transformation in research communication. The PLOS suite of journals contain rigorously peer-reviewed Open Access research articles from all areas of science and medicine, together with expert commentary and analysis. In addition to journals, the organization advances innovations in scientific publishing through Collections, Communities and The PLOS Blog Network. Founded to catalyze a revolution in scientific publishing by demonstrating the value and feasibility of Open Access publication, PLOS is committed to innovative and forward-looking solutions to scientific communication. For more information, visit https://www.plos.org/